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69 A randomised comparison of VANTOBRA and TOBI in cystic
ﬁbrosis patients with chronic Pseudomonas aeruginosa infection
for pharmacokinetic and therapeutic equivalence
D. Sands1, E. Sapiejka2, H. Mazurek3, G. Gaszczyk4. 1Institute of Mother and
Child, CF Centre, Warsaw, Poland; 2CF Centre, Gdansk, Poland; 3CF Centre,
Rabka, Poland; 4Pulmonology and Allergology Centre, Karpacz, Poland
Objective: Inhalable tobramycin is an accepted therapy to treat chronic PA infection
in CF. Efﬁcacious twice daily inhalation is time-consuming for the affected patients.
The aim was to evaluate the comparability of VANTOBRA/Tolero with TOBI/PARI
LC PLUS regarding drug pharmacokinetics, clinical parameters, inhalation times
and safety proﬁle.
Methods: The drug/device combinations were compared in a randomised, two-
period, multi-centre, cross-over 14-week study. 58 CF patients4 years with chronic
PA infection were enrolled. Assessments included plasma/sputum AUC and Cmax,
reduction of PA CFU, FEV1 % pred, inhalation time and adverse reactions.
Results: Plasma mean AUC was 4.2 (VANTOBRA) and 4.9 mg×h/ml (TOBI).
Plasma mean Cmax for both drugs was 1.3mg/ml. Sputum mean Cmax was 1.95
(VANTOBRA) and 1.42mg/g (TOBI). A log10 CFU reduction of −1.77 vs. −1.70
was achieved with VANTOBRA and TOBI in treatment phase I and −1.30 vs. 0.12
in treatment phase II. FEV1 % pred increased by 8.2% (VANTOBRA) and by 4.8%
(TOBI), in treatment phase II by 2.40% vs. −0.44%. Mean time per inhalation was
4.4 min (VANTOBRA/Tolero) and 24.3 min (TOBI/PARI LC PLUS). No fatalities
occurred. All 4 SAEs were not drug-related. Expected side effects (bronchospasms,
tinnitus) were observed in each two VANTOBRA and TOBI patients.
Conclusion: Lower plasma AUC and higher sputum Cmax values of VANTOBRA
allowed a better control of PA infection and improved lung function without
jeopardizing patient safety. The efﬁcacy/safety proﬁle and reduced inhalation time
of VANTOBRA/Tolero may provide a signiﬁcant therapeutic beneﬁt for CF patients.
70 Use of an electronic monitoring system to generate objective
information on patients’ adherence to taking treatments of a novel
inhaled tobramycin solution (VANTOBRA)
D. Sands1, E. Sapiejka2, H. Mazurek3, G. Gaszczyk4. 1Institute of Mother and
Child, CF Centre, Warsaw, Poland; 2CF Centre, Gdansk, Poland; 3CF Centre,
Rabka, Poland; 4Pulmonology and Allergology Centre, Karpacz, Poland
Objective: Patient adherence to inhaled medications is important to interpret
clinical trial results. Self-reported diaries have a high potential for manipulation.
To provide a reliable tool to assess patient adherence to treatment, a monitoring
feature was developed and incorporated into a speciﬁc eFlow technology nebulizer.
VANTOBRA/Tolero was compared prospectively in a randomised study in cystic
ﬁbrosis patients with TOBI/PARI LC PLUS.
Methods: The conﬁguration’s key feature is an electronic chip card recording date,
time and duration of each nebulization session and cause for termination. The
nebulizer operates only by insertion of a valid chip card. Recorded data were
processed using PARI’s Patient Monitoring Software. Adherence is calculated as
the ratio of actual/planned inhalations and shown graphically per study day or
cumulatively.
Results: Data of 54/58 patients were analysed. Mean adherence was 99% for all
evaluable patients, 98% in patients >13 years and 99% in patients of 7−13 years
of age. The adherence rate was comparable in all treatment cycles, independent
whether the patient was randomized to receive VANTOBRA as the ﬁrst or second
treatment cycle. As per patient diary, the compliance in the TOBI group was 99%.
Mean time/inhalation was 4.4 min (VANTOBRA/Tolero) and 24.3 min (TOBI/PARI
LC PLUS).
Conclusion: The eFlow technology nebulizer with patient monitoring function
provides objective adherence data. The monitoring feature offers the potential to
distinguish whether an observed treatment failure is based on lack of drug efﬁcacy
or non-adherence to the prescribed treatment regimen.
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Recent studies showed that the paranasal sinuses can constitute a niche for bacteria.
To date no effective treatment for these bacteria is available. Off label administration
of nasal antibiotics may be an option. However, ﬁrst safety of this treatment has to
be established.
Objectives: With this pilot study in two patients the pharmacokinetic parameters
of nasal administered tobramycin were investigated.
Methods: In two hospitalised CF-patients, treated with intravenous tobramycin,
after a wash-out period, 320mg of tobramycin, dissolved in 200ml isotonic saline,
was administered to the nose using nasal lavage. Eleven venous blood samples
were collected and with a Liquid Chromatography Tandem Mass Spectometer (LC-
MSMS) method, serum tobramycin concentrations were determined. Tobramycin
pharmacokinetic parameters were calculated using the MW\Pharm software pack-
age. Systemic absorption was calculated by dividing AUC after nasal administration
by AUC after intravenous administration corrected for the administered dose.
Results: In patient 1, a female of 32 years old, the maximum concentration (Cmax)
of tobramycin was 0.027mg/L. This Cmax was reached 30 minutes after the
nasal lavage with tobramycin (tmax). In total 0.20% (0.62mg) of the tobramycin
was systemically absorbed. In patient 2, a male of 36 years old, the Cmax was
0.029mg/L. The tmax was 45 minutes and in total 0.16% (0.51mg) of tobramycin
was absorbed.
Conclusion: Nasal lavage with 320mg tobramycin did not result in toxic serum
levels. The results of two patients showed a fast absorption of tobramycin and a
slow elimination. Approximately 0.20% of the tobramycin was absorbed by the
sinonasal mucosa.
72 Inspiratory ﬂow characteristics of the T-326 dry powder inhaler
(DPI) in CF patients
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Pharmaceuticals Corp, San Carlos, United States; 3Novartis Pharma AG, Basel,
Switzerland; 4Novartis Pharmaceuticals Corp, East Hanover, United States
Objectives: Successful use of a DPI rests on factors including adequate inspiratory
ﬂow and volume to disperse the drug and achieve deposition in the lower airways.
We assessed inhalation proﬁles from CF patients over a wide range of age and
disease severity, using the T-326 Inhaler (resistance = 0.079 cm H2O
0.5 LPM−1).
We compared the results to a previous study of 96 CF patients who inhaled from
an inspiratory trainer with various resistances. In that study averaged data from the
0.07 and 0.12 cm H2O
0.5 LPM−1 resistances were considered representative of the
T-326 Inhaler.
Methods: A diverse and clinically stable CF population (n = 38) was recruited
according to age (6−11, 12−17 and 18 years) and lung function (FEV1 percent
predicted high: >60%, medium: 40−60%, low: <40%). An Inhalation Proﬁle
Recorder measured 4 inhalation proﬁles/patient, from which inspiratory time and
ﬂows were derived.
Results: All but one patient achieved a peak inspiratory ﬂow (PIF) >60 LPM. 87%








Inspiratory time, sec 1.6±0.6 1.2±0.3 1.6±0.5 2.1±0.6
Inhaled volume, L 1.6±0.7 1.1±0.3 1.5±0.5 2.2±0.7
PIF, LPM 82.8±14.1 83.5±13.3 76.1±10.7 89.2±16.0
Mean PIF and inhaled volume were comparable to averaged values seen with the
simulated inhaler (inhaled volume 1.7±0.7 L; PIF 76.4±15.1 LPM).
Conclusion: CF patients  6 years of age with a wide range of lung function can
generate sufﬁcient inspiratory volume and ﬂow to effectively inhale the content of
tobramycin capsules using the T-326 Inhaler.
